Key Points
- COO Roger Adsett sold 88,060 shares of Insmed on April 1 at an average price of $164.63 for about $14.5 million, reducing his stake by 45.19% to 106,810 shares (~$17.6M).
- The April sale follows additional insider sales in January–February (≈5,081 shares worth ~ $870k), indicating ongoing insider selling this year.
- For context, Insmed trades near $162, reported a quarterly loss (EPS -$1.54) despite 152.6% revenue growth, has a market cap of about $35 billion, and an average analyst price target of $212.67 (mostly Buy/Outperform ratings).
Insmed, Inc. (NASDAQ:INSM - Get Free Report) COO Roger Adsett sold 88,060 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the sale, the chief operating officer owned 106,810 shares in the company, valued at approximately $17,584,130.30. The trade was a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Roger Adsett also recently made the following trade(s):
- On Tuesday, February 3rd, Roger Adsett sold 791 shares of Insmed stock. The stock was sold at an average price of $156.17, for a total value of $123,530.47.
- On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $358,616.03.
- On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total value of $140,406.14.
- On Tuesday, January 6th, Roger Adsett sold 1,429 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $247,688.57.
Insmed Stock Performance
Shares of Insmed stock opened at $162.43 on Friday. The company's 50-day moving average price is $150.30 and its 200-day moving average price is $166.51. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75. The company has a market cap of $35.01 billion, a price-to-earnings ratio of -25.34 and a beta of 1.10.
Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same period last year, the company posted ($1.32) EPS. The business's revenue was up 152.6% on a year-over-year basis. On average, equities analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Insmed
Large investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC boosted its holdings in shares of Insmed by 8,052.6% in the 4th quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company's stock worth $21,493,000 after purchasing an additional 121,755 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in Insmed by 88.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 16,775 shares of the biopharmaceutical company's stock worth $2,920,000 after buying an additional 7,863 shares during the last quarter. Corient Private Wealth LLC boosted its stake in Insmed by 34.1% in the fourth quarter. Corient Private Wealth LLC now owns 20,865 shares of the biopharmaceutical company's stock worth $3,631,000 after buying an additional 5,305 shares in the last quarter. Keenan LLC purchased a new stake in Insmed in the fourth quarter worth approximately $369,000. Finally, Reflection Asset Management bought a new position in Insmed during the fourth quarter valued at approximately $30,000.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on the company. TD Cowen set a $241.00 price objective on Insmed in a research report on Thursday, December 18th. Mizuho raised their price target on Insmed from $204.00 to $206.00 and gave the company an "outperform" rating in a report on Wednesday, March 25th. Wolfe Research set a $167.00 price objective on Insmed and gave the stock an "outperform" rating in a report on Thursday, December 18th. Leerink Partners upped their price objective on shares of Insmed from $210.00 to $215.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 24th. Finally, Barclays raised their target price on shares of Insmed from $231.00 to $237.00 and gave the company an "overweight" rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Insmed currently has an average rating of "Buy" and an average price target of $212.67.
View Our Latest Analysis on Insmed
About Insmed
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
